ReviewFrontiers in cell and developmental biology2019
'Omics Approaches to Explore the Breast Cancer Landscape.
Review in Frontiers in cell and developmental biology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 59 citations in OpenAlex.
- Meta-analysis of gene expression disease signatures in colonic biopsy tissue from patients with ulcerative colitis.Scientific reports · 2021Pooled it
- Meta-Analysis and Experimental Studies Reveal Mitotic Network Activity Index (MNAI) as Breast Cancer Metastasis and Treatment Biomarker.Life (Basel, Switzerland) · 2025Article
- Review
- Comparative analysis of statistical and deep learning-based multi-omics integration for breast cancer subtype classification.Journal of translational medicine · 2025Article
- A comprehensive transcriptome based meta-analysis to unveil the aggression nexus of oral squamous cell carcinoma.Biochemistry and biophysics reports · 2025Article
- Down-regulation of ESRP2 inhibits breast cancer cell proliferation via inhibiting cyclinD1.Scientific reports · 2024Article
- Selective impact of ALK and MELK inhibition on ERα stability and cell proliferation in cell lines representing distinct molecular phenotypes of breast cancer.Scientific reports · 2024Article
- Identification ofTranslational cancer research · 2024Article
- Omics-Based Investigations of Breast Cancer.Molecules (Basel, Switzerland) · 2023Review
- An omics approach to delineating the molecular mechanisms that underlie the biological effects of physical plasma.Biophysics reviews · 2023Review
- Breast Cancer: How Hippotherapy Bridges the Gap between Healing and Recovery-A Randomized Controlled Clinical Trial.Cancers · 2023Article
- Review
- A functional genetic screen for metabolic proteins unveils GART and theFrontiers in endocrinology · 2023Article
- Microfluidic-based dynamic BH3 profiling predicts anticancer treatment efficacy.NPJ precision oncology · 2022Article
- Data integration and mechanistic modelling for breast cancer biology: Current state and future directions.Current opinion in endocrine and metabolic research · 2022Review
- Breast cancer in the era of integrating "Omics" approaches.Oncogenesis · 2022Review
- Clinically relevant CHK1 inhibitors abrogate wild-type and Y537S mutant ERα expression and proliferation in luminal primary and metastatic breast cancer cells.Journal of experimental & clinical cancer research : CR · 2022Article
- Inhibitory Effect of Ursolic Acid on the Migration and Invasion of Doxorubicin-Resistant Breast Cancer.Molecules (Basel, Switzerland) · 2022Article
- Fibroblast growth factor receptor signalling dysregulation and targeting in breast cancer.Open biology · 2022Review
- 'Breast Cancer Resistance Likelihood and Personalized Treatment Through Integrated Multiomics'.Frontiers in molecular biosciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Breast cancer incidence is increasing worldwide with more than 600,000 deaths reported in 2018 alone. In current practice treatment options for breast cancer patients consists of surgery, chemotherapy, radiotherapy or targeting of classical markers of breast cancer subtype: estrogen receptor (ER) and HER2. However, these treatments fail to prevent recurrence and metastasis. Improved understanding of breast cancer and metastasis biology will help uncover novel biomarkers and therapeutic opportunities to improve patient stratification and treatment. We will first provide an overview of current methods and models used to study breast cancer biology, focusing on 2D and 3D cell culture, including organoids, and on
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.